Myogenesis

Pusan National University's Breakthrough in Muscle Regeneration: Nanotech Scaffolding Supports Tissue Growth

Retrieved on: 
Friday, January 19, 2024
2D, Tetrahydrocannabinolic acid synthase, Engineering, B cell, Research, PLCL, SGK1, Associate, MXenes, DNA, PCM, NPS, Survival, Gene, Nitric oxide, Pusan National University, Cell proliferation, VML, Myopathy, Nitric oxide synthase, Nano-Micro Letters, Regeneration, Informatics, Health informatics, Myogenesis, Cell, Dietary supplement

To improve surgical outcomes, traditional muscle grafts are giving way to artificial scaffold materials, with MXene nanoparticles (NPs) standing out as a promising option.

Key Points: 
  • To improve surgical outcomes, traditional muscle grafts are giving way to artificial scaffold materials, with MXene nanoparticles (NPs) standing out as a promising option.
  • They are highly electrically conductive, can accommodate a wide range of functional groups, and have stacked structures that promote cell interactions and muscle growth.
  • They used DNA sequencing to reveal the genes and biological pathways activated by MXene NPs to aid in muscle regeneration.
  • "Within 5 to 10 years, this research may yield groundbreaking treatments for muscle injuries," Prof. Kim optimistically states.

Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research

Retrieved on: 
Monday, September 18, 2023
Health, Stem Cells, Other Health, Research, Science, Pharmaceutical, Biotechnology, SBS, Tissue, Bio, Culture, 3D, Multimedia, Cell, 2D, Data analysis, Myogenesis, Acquisition, Curi, Organoid, Electrophysiology, Patient safety, Drug discovery, Ecosystem, Safety, Medical imaging, Nautilus, Stingray, Pulse

Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery.

Key Points: 
  • Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery.
  • View the full release here: https://www.businesswire.com/news/home/20230918918911/en/
    Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research (Photo: Business Wire)
    The Nautilus and Stingray platforms are both available as standalone bioscience instruments.
  • Curi Bio’s mission of democratizing these once inaccessible approaches continues with the commercial launch of Nautilus and Stingray.
  • “At Curi Bio, our goal is to provide researchers with innovative, turnkey solutions to accelerate the discovery of new medicines,” said Dr. Nicholas Geisse, CEO of Curi Bio.

Curi Bio Launches MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts

Retrieved on: 
Tuesday, June 6, 2023
Health, Stem Cells, Other Health, General Health, Research, Science, Biotechnology, Tissue, Myopathy, Myogenesis, Duchenne muscular dystrophy, Myosin, Bio, Culture, 3D, Skeletal muscle, Ageing, Multimedia, Cell, 2D, Desmin, Neuromuscular disease, DMD, Organoid, Tissue engineering, Engineering, Drug discovery, Dystrophin, Emergency medical technician, Longevity, Fatigue, 3D printing, Vaccine, Medical imaging

Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.

Key Points: 
  • Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.
  • View the full release here: https://www.businesswire.com/news/home/20230606005566/en/
    Curi Bio Launches MantaReady™ 3D Skeletal Muscle Myoblasts – Ready to Cast Isogenic Control and Duchenne Muscular Dystrophy Human Myoblasts for 3D Engineered Muscle Tissue (Photo: Business Wire)
    The myoblast lines were developed in response to the growing demand for high quality iPSC-derived cells required for 3D skeletal muscle engineering.
  • “Through our innovative technology, we’re able to provide researchers with high-quality skeletal muscle cells that can be used to accelerate the drug discovery process and translational muscle biology research,“ said Curi Bio CEO Nick Geisse.
  • To learn more about how MantaReady iPSC-derived skeletal muscle cells can improve the predictive power of your experiments, or about Curi Bio’s other human-relevant preclinical platform technologies and services, please reach out at www.curibio.com/contact .

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, March 23, 2023
PGN, Heart, GLP, Myogenesis, Duchenne muscular dystrophy, Therapy, DM1, Muscular dystrophy, RCT, Clinical trial, SAD, American Academy, Research, Cell, CUG, Research and development, Development, CTG, DMD, Patient, EDO, Physician, Episcopal conference, Administration, DMPK, MAD, NHP, HV, American Academy of Neurology, IND, Conference, Caregiver, Disease, Pharmaceutical industry, Cryptocurrency, Neurology

In December 2022, PepGen announced IND-enabling preclinical data supporting the progression of PGN-EDODM1 for the treatment of DM1 into clinical studies.

Key Points: 
  • In December 2022, PepGen announced IND-enabling preclinical data supporting the progression of PGN-EDODM1 for the treatment of DM1 into clinical studies.
  • Net loss was $14.9 million for the three months ended December 31, 2022, compared to $7.1 million for the same period in 2021.
  • Net loss was $69.1 million for the year ended December 31, 2022, compared to $27.3 million for the same period in 2021.
  • PepGen had approximately 23.7 million shares outstanding on December 31, 2022

PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference

Retrieved on: 
Wednesday, March 22, 2023
PGN, Muscular Dystrophy Association, Dystrophin, Human, Myogenesis, MBNL1, Duchenne muscular dystrophy, DM1, Clinical trial, Pathology, SAD, Doctor of Philosophy, CTG, DMD, Patient, EDO, Episcopal conference, MAD, DdPCR, NHP, Research, MDA, HV, Conference, Pharmacology, Safety, Pharmaceutical industry, Vaccine

Even more encouraging was the increase in exon 51 skipping as measured by ddPCR in non-human primates (NHPs) dosed with PGN-EDO51 at 20 mg/kg.

Key Points: 
  • Even more encouraging was the increase in exon 51 skipping as measured by ddPCR in non-human primates (NHPs) dosed with PGN-EDO51 at 20 mg/kg.
  • PepGen is also presenting preclinical in vitro and in vivo pharmacology data from its DM1 program, PGN-EDODM1, in an oral presentation at MDA.
  • “Our PGN-EDODM1 preclinical data showed the potential of an investigational therapy designed to liberate MBNL1,” commented James McArthur, President and Chief Executive Officer of PepGen.
  • PepGen plans to report safety, correction of transcript mis-splicing and clinical data from the FREEDOM-DM1 trial in 2024.

Matrix F.T. hosts first public cultivated meat tasting in Dublin, Ohio

Retrieved on: 
Tuesday, March 14, 2023
Policy, Myogenesis, Meat, Food technology, Taste, Edible, Fishing, Matrix, Vaso

DUBLIN, Ohio, March 14, 2023 /PRNewswire/ -- Matrix F.T ., a leading developer of edible, animal component-free and customizable scaffolds and microcarriers for the alternative protein industry, hosted the first public cultivated meat tasting on March 9th at Vaso, in Dublin, Ohio.

Key Points: 
  • DUBLIN, Ohio, March 14, 2023 /PRNewswire/ -- Matrix F.T ., a leading developer of edible, animal component-free and customizable scaffolds and microcarriers for the alternative protein industry, hosted the first public cultivated meat tasting on March 9th at Vaso, in Dublin, Ohio.
  • The exclusive, invite-only event included industry innovation leaders, policy makers, investors and economic development professionals selected by Matrix F.T.
  • products: a hybrid, cultivated chicken bite and a plant-based sausage with a novel Matrix F.T.
  • To make the chicken bite, chicken myoblasts obtained from a Matrix F.T.

Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Health, Pharmaceutical, Branches of biology, Biology, Cytokines, Hepatocyte growth factor, HGF, Growth factor, Wound healing, Myogenesis, c-Met inhibitor, Helixmith

b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

Key Points: 
  • b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.
  • It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing.
  • In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.\nThe report \'Hepatocyte Growth Factor - Pipeline Review, H2 2020\' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.\nIt also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
  • Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 3, 4 and 3 respectively.\nThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities\n'